Eli Lilly and Regeneron asking regulators to expand authorization of their drugs based on the new findings
IgG Level in Convalescent Plasma Affects COVID-19 Death Risk
Risk for death reduced with higher versus lower levels of anti-SARS-CoV-2 IgG, but only in patients not receiving mechanical ventilation
Early High-Titer Plasma Reduces Progression of COVID-19
Early administration of high-titer convalescent plasma against SARS-CoV-2 reduces progression in mildly ill older adults
Red Cross Issues Call for More Blood Plasma to Treat COVID-19 Patients
People who have recovered from COVID-19 may have antibodies in their plasma that could boost immunity in current patients
COVID-19 Outcomes Not Improved With Convalescent Plasma
Clinical status, mortality did not differ for convalescent plasma versus placebo in adults with severe COVID-19 pneumonia
Nebulized Interferon Beta-1a Promising for COVID-19
Adults hospitalized for COVID-19 receiving SNG001 versus placebo more likely to show clinical improvement
Convalescent Plasma Has Limited Benefit for Moderate COVID-19
Randomized phase II trial shows no drop in progression to severe disease, all-cause deaths